Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
Novo Inks Collab Pact with Kasugai City on Obesity Measures
Novo Nordisk Pharma has joined hands with Kasugai City in Aichi Prefecture to jointly push measures to address obesity towards extending the healthy longevity of residents. The company’s president Kasper Bødker Mejlvang airs hopes that their collaboration will be a…
To read the full story
Related Article
- Novo Hooks Up with Hirosaki City on Obesity Program for Young Adults
August 29, 2025
- Novo Partners with Asahikawa City on Obesity Measures
April 22, 2025
BUSINESS
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
- Oncolys’ Oncolytic Virus Telomelysin Gets Orphan Status in Japan
December 15, 2025
- Radicut Suspension Approved in South Korea for ALS
December 15, 2025
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…